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Increased concentrations of interleukin-6 (IL-6) have been found in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and 
crystal-related joint deseases. It is therefore of great interest to identify the cells responsible for the production of IL-6, and to investigate whether 
IL-6 plays a role in the pathogenesis of degenerative or inflammatory joint diseases. Here we show that human interleukin-lfl (IL-lfl) induces IL-6 
synthesis and secretion in differentiated human chondrocytes. In organ cultures resembling closely the in vivo system 106 chondrocytes incubated 
with 100 units of interleukin-lfl per ml of medium led to the release of 6 x 103 units of IL-6 within 24 h. Chondrocytes cultured in agarose or 
as monolayers similary incubated with IL-lfl produced even higher amounts of IL-6:70 x 103 units per 106 cells within 24 h. The induction of 
IL-6 synthesis by IL-lfl was also shown at the mRNA level. IL-6 secreted by stimulated chondrocytes showed heterogeneity upon Western blot 
analysis. 
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1. INTRODUCTION 
Chondrocytes are actively involved in the regulation 
of the dynamic balance between synthesis and degrada- 
tion of proteoglycans, which besides collagen constitute 
the major components of the extracellular matrix of 
cartilage (reviewed in [1,2]). This balance is disturbed 
in rheumatoid arthritis and other inflammatory or 
degenerative joint diseases [3,4]. Recent studies from 
several laboratories have demonstrated that the steady 
state metabolism of chondrocytes is affected by factors 
such as insulin-like growth factors IGF-I and IGF-II 
[5,6], transforming growth factor [7,8], and 
interleukin- 1 (IL- 1) [9-15]. Increased concentrations of 
interleukin-6 have been found in the synovial fluid of 
patients with osteoarthritis, rheumatoid arthritis, and 
crystal-related joint diseases [16-18]. Since IL-1 ap- 
pears to be the major stimulator of interleukin-6 (IL-6) 
synthesis in many different cell types (reviewed in [19]), 
we asked the question, whether chondrocytes can also 
be stimulated to synthesize IL-6. 
Here we present data which show that human IL-1 
induces IL-6 synthesis and secretion in differentiated 
human chondrocytes. 
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2. MATERIALS  AND METHODS 
2.1. Chemicals 
Collagenase CLS II from CI. histolyticum was purchased from 
Worthington (USA). [6-3H]Thymidine (74 GBq/mmol) was obtained 
from Amersham International (Amersham, UK). Fetal calf serum 
(FCS), Opti-MEM 1, and Ultroser G were from Gibco (Eggenstein, 
FRG). Low-gelling-temperature agarose was from Sigma (Munich, 
FRG). An IL-l-specific ELISA was obtained from Research and 
Diagnostics Systems (Minneapolis, USA). RhlL-1 (1.3 × 10 7 U/mg) 
was kindly supplied by Dr A. Shaw (Glaxo, Institute for Molecular 
Biology SA, Geneva, Switzerland). 
2.2. In vitro culture of human chondrocytes 
Cartilage was obtained from the knee joint of a 40-year-old pa- 
tient, who had died from an oesophageal carcinoma. The cartilage 
appeared normal by morphological examination. For organ cultures 
pieces of cartilage of equal size were embedded in 0.75°/0 low-gelling- 
temperature agarose and cultured in Opti-MEM 1 supplemented with 
10070 FCS, 10/0 Ultroser G, 1 #g/ml insulin and 50/zg/ml ascorbic 
acid. For agarose cultures chondrocytes were isolated by collagenase 
treatment essentially as described [20,21]. Culture medium was the 
same as described above. 
Viability of chondrocytes was measured by the Trypan-blue dye ex- 
clusion test. In all experiments he viability was >98%. 
2.3. IL-6 assay 
The IL-6 assay was performed using the murine plasmacytoma cell 
line B9 kindly provided by L. Aarden (Amsterdam, The Netherlands) 
[22]. Briefly, 5 × 103 B9 cells were incubated with the supernatants 
from chondrocytes in the presence of 0.5/~Ci [3H]thymidine and in- 
corporation of radioactivity was measured. One B9 unit/ml is the 
concentration that leads to half-maximal [3H]thymidine incorpora- 
tion in the assay. Under our assay conditions 150-500 fg/ml of IL-6 
can be detected. 
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2.4. Northern blot analysis 
Total RNA was isolated from chondrocytes cultured as monolayers 
essentially as described [23]. 5 ~tg of RNA were used for Northern 
blotting. Hybridization was performed with the 1.1 kb EcoRI- 
fragment of the IL-6 eDNA clone [24] labeled by random priming 
[25]. 
2.5. Western blot analysis 
Western blotting was performed according to [26]. The blot was in- 
cubated with a specific rabbit anti-IL-6 antiserum (1: 1000 dilution). 
After washing with PBS containing 0.05% Tween 20, blots were in- 
cubated with a second antibody (goat anti-rabbit IgG peroxidase con- 
jugated) for 1 h at room temperature. Blots were washed and finally 
stained with aminoethylcarbazole as a substrate. 
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3. RESULTS AND DISCUSSION 
Various experimental systems have been used for in 
vitro studies of chondrocyte function. Thus far, 
monolayer cultures have widely been used in spite of 
the fact that they represent a rather artificial system [2]. 
Therefore, other systems have been developed, which 
reflect more closely the in vivo situation of human 
chondrocytes in cartilage. In contrast to monolayer 
cultures chondrocytes embedded in agarose have been 
described to maintain their differentiated phenotypes 
[2]. Organ cultures resemble most closely the in vivo 
system, because the chondrocytes remain in their ex- 
tracellular matrix. 
We have studied the effect of recombinant human 
IL-I (rhIL-1) on chondrocytes in organ culture, in 
agarose culture and as monolayers in respect o IL-6 
production. Fig. 1 shows the t ime-dependent IL-6 syn- 
thesis and secretion by chondrocytes in organ culture. 
Addit ion of 100 units of rhIL-1 per ml of culture 
medium resulted in a 4-fold increase in IL-6 concentra- 
tions within 24 h. Organ cultures without exogeneous 
rhIL-1 also showed a slight increase in IL-6 production. 
We excluded that this increase is due to an IL-1 con- 
taminat ion of FCS by measuring IL-1 concentrations. 
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Fig. 1. RhlL-1 induced IL-6 synthesis in human chondrocytes in
organ culture. Pieces of 850 mg (control) and 875 mg (rhIL-1) of 
cartilage (wet weight equivalent o 6.4 × 106 and 6.6 × 106 
chondrocytes, respectively) were embedded in 2.5 ml of low-gelling- 
temperature agarose. Total volume of medium (see section 2) was 
7.5 ml. After a preincubation period of 3 days rhIL-1 was added at 
a final concentration of 100 U/ml. At the times indicated in the 
figure IL-6 concentrations were determined. 
Fig. 2. IL-6 production of human chondrocytes in agarose cultures 
after stimulation with rhlL-1. Chondrocytes were obtained from 
cartilage by collagenase treatment (see section 2) and embedded in
low-gelling-temperature agarose at a density of 1 x 106 cells per ml 
of gel. Each dish contained 3 x 106 chondrocytes in 3 ml of agarose 
overlaid with 5 ml of medium resulting in a total volume of 8 ml 
medium. After a preincubation period of 10 days 50 U/ml of rhlL-1 
were added. At the times indicated medium was taken for IL-6 
determinations. 
Using an ELISA with a detection limit of 30 pg cor- 
responding to 0.4 units of IL-1 per ml, no IL-1 could 
be detected in the supernatants. Since lipopolysac- 
charide (LPS) is a weak stimulator of IL-6 synthesis in 
human chondrocytes (unpublished results) and since it 
is well known that most batches of FCS are con- 
taminated by LPS, it is possible that the slight IL-6 in- 
duct ion observed in our controls may be due to the 
action of LPS. 
Compared to organ cultures an even stronger 
st imulation of IL-6 synthesis by rhlL-1 was observed in 
agarose cultures. A 7-fold increase in IL-6 concentra- 
tions was found after 24 h (Fig. 2). It can be seen from 
Fig. 2 that the IL-6 release is observed after a lag of 
16 h. This lag may be due to the requirement of de 
novo synthesis of IL-6 and also to the fact that the 
released IL-6 is primari ly trapped within the ex- 
tracellular matrix and is detectable only after diffusion 
into the medium. 
In monolayer cultures of human chondrocytes from 
the first passage a 5-fold increase in IL-6 production 
was measured (Table I). A similar increase was found 
Table I 
RhlL-l-dependent induction of IL-6 synthesis and secretion in 
human chondrocytes in monolayer cultures 
IL-6 production 
(U × 10-3/106 cells/24 h) 
Control 15.5 
RhIL-1 (50 U/ml) 71.1 
Chondrocytes were isolated as described for agarose cultures and 
plated on 9.6 cm 2 dishes at a density of 106 cells per dish and 5 ml 
of medium. After 10 days in culture cells were stimulated with 
50 U/ml of rhlL-1 and 1L-6 concentrations were measured 
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Fig. 3. Northern blot analysis of IL-6 mRNA from human 
chondrocytes in monolayer culture after stimulation with rhlL-1. 
Human chondrocytes in monolayer culture were incubated without 
(co) and with 50 U/ml rhlL-1 for 24 h. Total RNA was isolated and 
subjected to Northern analysis as described in section 2. 
for IL-6 mRNA in IL - l - s t imulated chondrocytes 
(Fig. 3). 
When the IL-6 released from chondrocytes in 
monolayer  culture was analyzed by SDS-PAGE and 
subsequent Western blott ing heterogeneity of IL-6 was 
observed (Fig. 4). We [27,28] and other investigators 
[29] have recently described such a microheterogeneity 
for IL-6 secreted by LPS-st imulated human monocytes,  
rh lL - l -ac t ivated  human f ibroblasts or endothel ia l  cells. 
By use of  deglycosylat ing enzymes and the N- 
g lycosylat ion inhibitor tunicamycin,  it was shown that 
the microheterogeneity of  IL-6 is the result o f  N- and 
O-glycosylat ion [27-29]. A detai led analysis of  the dif- 
ferently glycosylated forms of  IL-6 is in progress. 
It is evident from the data presented that rhlL-1 is a 
potent  inducer of  IL-6 in human chondrocytes in organ 
cultures, in agarose cultures and in monolayers.  
Therefore,  the increased IL-6 concentrat ions determin- 
ed in synovial fluids of  patients with in f lammatory  
jo int  diseases [18] may result f rom the st imulat ion of  
chondrocytes.  A l though IL-6 can be synthesized by a 
number  of  dif ferent cells after appropr iate  st imulat ion 
[19,30], endothel ia l  cells, f ibroblasts and 
monocytes /macrophages  are presently believed to be 
the major  sources of  IL-6 during in f lammatory  
diseases. 
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Fig. 4. Microheterogeneity of IL-6 synthesized and secreted by 
human chondrocytes in monolayer culture after stimulation with 
rhlL-1. Human chondrocytes in monolayer culture incubated 
without fetal calf serum and Ultroser G were stimulated with 
75 U/ml rhlL-1 for 24 h. One ml of IL-6-containing supernatant was 
concentrated and subjected to SDS-PAGE and Western blotting. For 
comparison IL-6 secreted by IL-1 (75 U/ml) stimulated human lung 
fibroblasts has been included in the figure. N/O- and O- indicate N- 
plus O- and O-glycosylated forms of IL-6, respectively. 
F rom the results of  this study it is evident that 
st imulated chondrocytes are also potent IL-6 producing 
ceils. 
It has been shown that IL-1 (a potent inducer of  IL-6 
synthesis) is found in high concentrat ions in the 
synovial  fluid of  patients with in f lammatory  jo int  
diseases [31,32]. Chondrocytes respond to IL-1 by the 
release of  hydrolases [33] and in turn an increase of  
proteoglycan degradat ion [13,14]. Furthermore,  pro- 
teoglycan synthesis is impaired [34]. It has to be 
clar i f ied whether these effects are due to the direct ac- 
t ion of  IL-1 on the chondrocytes or whether they are 
mediated by IL-6 involving an autocrine mechanism. 
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